Agios Pharmaceuticals upgraded to neutral at Goldman Sachs on Pyrukynd outlook [Seeking Alpha]
Agios Pharmaceuticals, Inc. (AGIO)
Last agios pharmaceuticals, inc. earnings: 4/30 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.agios.com/investor-overview
Company Research
Source: Seeking Alpha
Agios Pharmaceuticals upgraded to neutral at Goldman Sachs on Pyrukynd outlookNov. 17, 2022 11:34 AM ETAgios Pharmaceuticals, Inc. (AGIO)PFENVOBy:Jonathan BlockSA News EditorMatteo ColomboGoldman Sachs has upgraded Agios Pharmaceuticals (NASDAQ:The firm also boosted its price target to $32 from $17 (~18% upside based on Wednesday's close).Analyst Salveen Richter said that phase 3 data of Pyrukynd in α- and �-thalassemia in 2H 2023 could help the stock due to a lack of approved therapies. She sees peak sales of $759M in this indication in 2033.She is also looking forward to phase 2 data in sickle cell disease in 1H 2023 as it could differentiate itself from Novo Nordisk's (Richter projects $739M in peak sales in this indication in 2033.Pyrukynd was launched earlier this year in the US for hemolytic anemia with pyruvate kinase deficiency. While Richter assumes peak sales in the indication of $241M in 2033, "we reiterate our cautious view given patient identification headwinds and resp
Show less
Read more
Impact Snapshot
Event Time:
AGIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AGIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AGIO alerts
High impacting Agios Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
AGIO
News
- Agios to Webcast Conference Call of First Quarter 2024 Financial Results on May 2, 2024GlobeNewswire
- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- Agios Publishes 2024 Environmental, Social and Governance (ESG) Report [Yahoo! Finance]Yahoo! Finance
- Agios Publishes 2024 Environmental, Social and Governance (ESG) ReportGlobeNewswire
- We Think Agios Pharmaceuticals (NASDAQ:AGIO) Can Afford To Drive Business Growth [Yahoo! Finance]Yahoo! Finance
AGIO
Earnings
- 11/2/23 - Beat
AGIO
Sec Filings
- 4/10/24 - Form 4
- 3/11/24 - Form 4
- 3/7/24 - Form 4
- AGIO's page on the SEC website